From Evidence to Access: Aligning Strategy with Payer Decision-Making

For manufacturers, achieving access can sometimes be framed as a relatively straightforward objective: generate strong evidence, demonstrate value and secure coverage.

In practice, payer decision-making is much more complex. Access emerges from a connected series of clinical, financial, contracting and operational decisions. Different stakeholders may evaluate the same product through different lenses, and a positive coverage decision does not necessarily translate into straightforward patient access. That distinction has important implications for market access strategy.

Rather than focusing only on whether the evidence demonstrates value, manufacturers also need to consider how that evidence will be used. Who is making the decision? What question are they trying to answer? What information will matter at that point? And what additional decisions will determine how coverage is ultimately implemented?

Understanding that process can help manufacturers build evidence and engagement strategies that are better aligned with how access actually takes shape.

Payer assessment can begin well before regulatory approval. Health plans monitor pipelines, evaluate areas of unmet need and begin anticipating potential budget impact during clinical development and pre-approval planning. At approval, the label, available clinical evidence, price and benefit or reimbursement pathway help frame the review. New evidence, new indications, utilization patterns, guidelines, competition and contracting can then prompt reassessment after launch.

Within that process, different groups are responsible for different decisions.

One useful way to understand payer review is to separate two related questions.

The first is whether a product should be covered. That assessment can include FDA approval, guidelines or compendia support, the quality and maturity of the clinical evidence, comparative evidence versus available alternatives, unmet need and place in therapy.

The second is how the product should be covered. That introduces another set of considerations: which patients are most likely to benefit, treatment history and sequencing, budget impact and total cost of care, coding and reimbursement, site of care, implementation burden, formulary placement and utilization management.

The distinction matters because evidence that supports the first decision may not fully answer the second.

Pivotal clinical trial endpoints may establish efficacy and support regulatory approval, but payers may still need comparative evidence, economic analyses, real-world outcomes or information about appropriate patient identification to determine the conditions under which a therapy should be accessed.

The strategic opportunity is not simply to generate more evidence. It is to generate and communicate evidence with a clearer understanding of the specific decisions it will eventually need to support.

There is no single payer pathway that applies equally across products. Traditional pharmacy-benefit drugs may move through a formulary process involving clinical review followed by decisions around tier placement, prior authorization, step therapy, exclusion and contracting.

Medical-benefit drugs introduce different considerations. Access can depend on medical policy, coding, reimbursement, drug acquisition, provider economics and site of care. At launch, for example, the absence of a product-specific code can create manual review and payment uncertainty for providers.

Medical devices introduce another decision structure. Value analysis committees may evaluate clinical performance alongside upfront costs, workflow, training requirements, supply chain considerations and operational fit.

Product type can change the decision logic as well. Rare disease therapies may place greater emphasis on unmet need, patient identification and treatment outcomes, while products entering crowded classes may face greater scrutiny around differentiation and net cost. Specialty therapies may span both pharmacy and medical benefits, adding specialty pharmacy networks and site-of-care considerations.

The implication is that evidence and engagement should reflect the pathway the product will actually encounter. A value story developed without that context risks answering the wrong questions or reaching the right stakeholder too late.

Manufacturers invest significant effort in developing an overarching value story. That strategic foundation remains important, but different payer stakeholders may assess value differently. Clinical stakeholders may focus on comparative efficacy and safety, place in therapy and the appropriate patient population. Economic stakeholders may be more focused on budget impact, cost offsets and total cost of care.

Contracting stakeholders may evaluate net cost, competitive position and the terms that could support preferred access. Operational stakeholders may need information about coding, reimbursement, site of care, utilization management criteria and implementation requirements.

Trying to give every audience the same information in the same way can make the most relevant evidence harder to identify. A more useful approach starts with a common strategic foundation and translates it into role-specific information based on the decision in front of each stakeholder.

That does not necessarily require creating an entirely different asset for every audience. It requires understanding the questions, incentives and responsibilities of each stakeholder well enough to emphasize the information most relevant to their role.

There can be a natural tendency to lead payer discussions with the evidence that is most readily available, often pivotal clinical trial data developed around regulatory requirements. But the information needed to secure approval is not always the same information needed to support payer decision-making.

Payers may also need comparative and real-world outcomes, budget impact, cost offsets or evidence that helps them understand how a product is likely to perform in populations similar to their own. They also look to independent sources, including published guidelines, peer-reviewed clinical trials, government sources and published real-world evidence, alongside manufacturer-provided information.

How the evidence is presented matters as well. Comprehensive dossiers remain important, but payer research discussed in the webinar also points to demand for information that is more concise, interactive and easier to access when a decision-maker needs it.

The goal should not be to deliver as much information as possible. It should be to make relevant evidence easier to find, evaluate and apply at the point of decision.

If payer evaluation occurs throughout the product lifecycle, engagement should evolve along with it. Before launch, manufacturers can build awareness of the pipeline and potential budget impact, discuss unmet need and emerging evidence, and understand decision timing and key stakeholders.

At launch, engagement can become more specific to formulary or policy review, role-specific value communication, coding and implementation.
After launch, new clinical data, real-world evidence, guideline changes, competitive entrants and payer experience can all create reasons to revisit the access strategy.

This shifts payer engagement away from episodic outreach concentrated around launch and toward a more continuous model tied to evidence and decision milestones. It also creates an opportunity to use payer insights earlier. Understanding how decision-makers interpret emerging evidence can help inform evidence planning, including the endpoints, comparators and real-world evidence that may ultimately matter to access.

More targeted engagement also begins with understanding the decision ecosystem.

That intelligence can inform not only who manufacturers engage, but also what they discuss and when.

It can also inform different approaches to engagement, including payer-to-payer perspectives, targeted evidence exchanges and working sessions focused on challenges payers are already trying to solve.

The goal is not more engagement for the sake of frequency. It is engagement that is relevant to the stakeholder and aligned with the moments when new information can help inform a decision.

Moving from evidence to access requires more than demonstrating that a product has value. It requires understanding how different stakeholders interpret that value, what additional questions they must answer and how their individual decisions combine to shape access.

For manufacturers, that means starting with the decision rather than the deliverable.

Building market access strategy around those questions can make evidence generation more targeted, engagement more relevant and value communication easier for payers to apply.

Want to explore the topic further? Watch the on-demand webinar, From Evidence to Access: Understanding Payer Decisions and Evolving Engagement Strategies.